Business Context and Reporting Period
This Form 8-K is a current report filed by Pieris Pharmaceuticals, Inc. on September 19, 2018. The registrant is a Nevada corporation with principal executive offices in Boston, MA. The filing serves as a Regulation FD disclosure regarding the presentation of preclinical data.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on scientific data disclosure rather than financial performance.
Material Changes
There are no material financial changes reported in this document. The significant event is the presentation of preclinical data regarding the company's candidate PRS-060.
Guidance, Outlook, and Risks
- Management Commentary: The company presented preclinical data for PRS-060 on September 19, 2018.
- Exhibits: A conference poster dated September 2018 detailing the data is included as Exhibit 99.1.
- Legal Status of Information: The information under Item 7.01 and the attached exhibits are not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and are not incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Review Exhibit 99.1 (Conference Poster) for the specific preclinical data regarding PRS-060.
- Verify the clinical development timeline for PRS-060 in subsequent filings, as this 8-K only confirms data presentation.
- Note that this disclosure is not incorporated by reference into Securities Act filings unless explicitly cited.